RNA today
$7.96-$0.27 (-3.28%)close Nov 11, 2026Trend
DailyUptrend (starting)
4 hourStrong Bearish
1 hourStrong Bearish
15 minStrong Bearish
5 minStrong Bearish
Daily trend turns down below $7.54
Key levels
Resistance$8.99
Resistance$8.50
Support$7.88
Support$6.79
Latest news & SEC filings
ProductAtrium Therapeutics to present nonclinical ATR 1072 data at AHA Scientific Sessions 2026
All RNA news →Nasdaq · Healthcare
Atrium Therapeutics, Inc. (RNA)
What Is the Price Target for RNA?
SEPT Low Target
$15.00
SEPT Mid Target
$25.00
SEPT High Target
$25.00
Analyst Consensus
$25.00
Is RNA a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for RNA.
Start Free Trial →Is RNA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$25.00
12
Moat Score
NONE
1/9
Piotroski Score
-0.1
Altman Z-Score
What Is Smart Money Doing with RNA?
Insider Signal
SELLING
0 buys / 12 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Hughes Steven George | officer | Sale | 21,459 | $192K | Sep 18, 2026 |
| Flanagan W. Michael | director | Sale | 22,812 | $204K | Sep 18, 2026 |
| Boyce Sarah | director | Sale | 126,418 | $1.1M | Sep 18, 2026 |
| Gallagher Kathleen P. | director officer | Sale | 11,632 | $104K | Sep 18, 2026 |
| Younis Husam | officer | Sale | 11,216 | $100K | Sep 18, 2026 |
| Kenney Stephanie | officer | Sale | 2,375 | $21K | Sep 18, 2026 |
| Winslow Brendan R. | officer | Sale | 6,742 | $60K | Sep 18, 2026 |
| Hoyos Rocio Martin | officer | Sale | 8,320 | $74K | Sep 18, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →RNA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for RNA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for RNA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:00 | $7.96 | 14,654 | $$117K | MIDPOINT |
| 20:00:41 | $7.95 | 2,000 | $$16K | SELL |
| 19:30:08 | $7.95 | 1,257 | $$10K | BUY |
| 18:09:18 | $8.05 | 3,000 | $$24K | SELL |
| 18:07:19 | $8.07 | 2,000 | $$16K | SELL |
5 dark pool trades shown · $$183K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Atrium Therapeutics, Inc. (RNA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →RNA — frequently asked questions
What is RNA stock price today?
Atrium Therapeutics, Inc. (RNA) is at $7.96, down 3.28% (-$0.27) at the Nov 11, 2026 close.
Why is RNA stock moving today?
Latest RNA news — Nov 2, 2026: Atrium Therapeutics to present nonclinical ATR 1072 data at AHA Scientific Sessions 2026
What is the RNA price target?
The average analyst price target for RNA is $25.00, ranging from $15 to $25, based on 5 analysts. Latest: HC Wainwright & Co. maintains on Oct 28, 2026.
What do analysts rate RNA?
Analyst ratings for RNA: 0 Buy, 6 Hold, 0 Sell — consensus Hold.
Did RNA beat earnings?
RNA last reported on Aug 13, 2026: EPS -$1.18 vs -$1.42 expected — a beat of 16.9%.
Does RNA pay a dividend?
RNA does not currently pay a dividend.
What are RNA support and resistance levels?
Support: $7.88, $6.79, $6.14. Resistance: $8.50, $8.99, $9.66.
What are insiders doing with RNA?
Insider activity: SELLING, 0 buys and 12 sells in the last 90 days.
What is the latest news on RNA?
Nov 2, 2026: Atrium Therapeutics to present nonclinical ATR 1072 data at AHA Scientific Sessions 2026